There may be significant differences among countries in the design of green finance policies, pharmaceutical price regulation, and essential drug schemes, which could lead to differences in policy outcomes.
← all excerpts
Digital transformation, green finance, and pharmaceutical affordability in China: a health economics perspective.
1
—
—